These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 12542005)

  • 1. A promising new anti-HCV protease inhibitor.
    Sulkowski M
    Hopkins HIV Rep; 2003 Jan; 15(1):7. PubMed ID: 12542005
    [No Abstract]   [Full Text] [Related]  

  • 2. Worth the wait. New, more effective therapies for hepatitis C are on the way.
    Learned J
    Posit Aware; 2011; 23(1):15-8. PubMed ID: 21314021
    [No Abstract]   [Full Text] [Related]  

  • 3. Hepatitis drug reduces effects of HIV medications.
    Kuehn BM
    JAMA; 2012 May; 307(20):2138. PubMed ID: 22618906
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of hepatitis C 2010: a focus on protease inhibitors.
    Lemon M
    S D Med; 2010 Jun; 63(6):214-5. PubMed ID: 20853592
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmacokinetics and antiviral activity of PHX1766, a novel HCV protease inhibitor, using an accelerated Phase I study design.
    Hotho DM; de Bruijne J; O'Farrell AM; Boyea T; Li J; Bracken M; Li X; Campbell D; Guler HP; Weegink CJ; Schinkel J; Molenkamp R; van de Wetering de Rooij J; van Vliet A; Janssen HL; de Knegt RJ; Reesink HW
    Antivir Ther; 2012; 17(2):365-75. PubMed ID: 22293533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
    Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R
    Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of boceprevir, a direct-acting NS3/4A protease inhibitor for treatment of chronic hepatitis C infections.
    Venkatraman S
    Trends Pharmacol Sci; 2012 May; 33(5):289-94. PubMed ID: 22521415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focus on hepatitis. HCV protease inhibitor does well in early clinical trial.
    Carter M
    IAPAC Mon; 2006 Feb; 12(2):50-1. PubMed ID: 17252625
    [No Abstract]   [Full Text] [Related]  

  • 9. Safely treating hepatitis C in patients with HIV or hepatitis B virus coinfection.
    Jafari A; Khalili H; Izadpanah M; Dashti-Khavidaki S
    Expert Opin Drug Saf; 2015 May; 14(5):713-31. PubMed ID: 25813487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombotic microangiopathy (TMA) in a patient treated with antiviral therapy for hepatitis C.
    Evans R; Pavan M; Suri D; Harber M
    BMJ Case Rep; 2014 Apr; 2014():. PubMed ID: 24706704
    [No Abstract]   [Full Text] [Related]  

  • 11. Prisoners treated for hepatitis C with protease inhibitor, New York, USA, 2012.
    Moorjani H; Koenigsmann C; Kim MJ; Spaulding AC
    Emerg Infect Dis; 2015 Jan; 21(1):186-8. PubMed ID: 25531029
    [No Abstract]   [Full Text] [Related]  

  • 12. Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1.
    Salmon-Ceron D; Arvieux C; Bourlière M; Cacoub P; Halfon P; Lacombe K; Pageaux GP; Pialoux G; Piroth L; Poizot-Martin I; Rosenthal E; Pol S; ; ; ;
    Liver Int; 2014 Jul; 34(6):869-89. PubMed ID: 24138548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caution with new oral hepatitis C drugs.
    Soriano V; Esposito I
    AIDS Rev; 2015; 17(2):121-2. PubMed ID: 26035170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of HCV protease inhibitors.
    Chen KX; Njoroge FG
    Curr Opin Investig Drugs; 2009 Aug; 10(8):821-37. PubMed ID: 19649927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hepatitis C treatment in special patient groups].
    Berenguer M; Jorquera F; Ángel Serra M; Sola R; Castellano G
    Gastroenterol Hepatol; 2014 Jul; 37 Suppl 1():23-36. PubMed ID: 25907435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.
    Mo H; Yang C; Wang K; Wang Y; Huang M; Murray B; Qi X; Sun SC; Deshpande M; Rhodes G; Miller MD
    J Viral Hepat; 2011 May; 18(5):338-48. PubMed ID: 20456634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of hepatitis C: new inhibitors as hammers against HCV].
    Bublak R
    MMW Fortschr Med; 2013 Jun; 155 Suppl 1():10-1. PubMed ID: 23961643
    [No Abstract]   [Full Text] [Related]  

  • 18. Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.
    de Bruijne J; van Vliet A; Weegink CJ; Mazur W; Wiercinska-Drapało A; Simon K; Cholewińska-Szymańska G; Kapocsi J; Várkonyi I; Zhou XJ; Temam MF; Molles J; Chen J; Pietropaolo K; McCarville JF; Sullivan-Bólyai JZ; Mayers D; Reesink H
    Antivir Ther; 2012; 17(4):633-42. PubMed ID: 22427481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The era of direct-acting antivirals has begun: the beginning of the end for HCV?
    Vachon ML; Dieterich DT
    Semin Liver Dis; 2011 Nov; 31(4):399-409. PubMed ID: 22189979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.